---
title: "301393.SZ (301393.SZ) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/301393.SZ/news.md"
symbol: "301393.SZ"
name: "301393.SZ"
parent: "https://longbridge.com/zh-HK/quote/301393.SZ.md"
datetime: "2026-03-16T23:49:43.818Z"
locales:
  - [en](https://longbridge.com/en/quote/301393.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301393.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301393.SZ/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/301393.SZ/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/301393.SZ/news.md)


# 301393.SZ (301393.SZ) — 相關新聞

### [](https://longbridge.com/zh-HK/news/263213016.md)
*2025-10-29T05:15:40.000Z*
> The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tige

### [Highfine released its performance for the first three quarters, with a net profit attributable to the parent company of 99.2383 million yuan, an increase of 3.01%](https://longbridge.com/zh-HK/news/263101297.md)
*2025-10-28T13:19:02.000Z*
> Highfine released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 43

### [Highfine Biotech released its performance for the first half of the year, with a net profit attributable to the parent company of 75.8848 million yuan, an increase of 15.31%](https://longbridge.com/zh-HK/news/254975786.md)
*2025-08-28T10:18:06.000Z*
> According to the Zhitong Finance APP, Highfine released its semi-annual report for 2025, showing an operating income of 

### [On July 14th, Highfine will unlock and list 1.863 million shares, accounting for 3.82% of the circulating A-shares](https://longbridge.com/zh-HK/news/247941884.md)
*2025-07-10T07:22:26.000Z*
> Highfine Biotechnology will unlock and list 1.863 million shares on July 14, 2025, accounting for 3.82% of the circulati

### [Highfine: Plans to acquire 100% equity of Hangzhou Foster for 160 million yuan](https://longbridge.com/zh-HK/news/247339756.md)
*2025-07-04T15:18:02.000Z*
> Highfine announced that the company plans to use 160 million yuan of its own or raised funds, to be carried out in two p

### [](https://longbridge.com/zh-HK/news/241135999.md)
*2025-05-21T01:49:20.000Z*
> The CRO concept saw a short-term surge, with HC CHEMICAL hitting the limit up, and Kingchem, ChemPartner, R&G Pharma, Hi

### [GLP-1 patent catalysis, have peptide synthesis reagents become the new darling?](https://longbridge.com/zh-HK/news/239672146.md)
*2025-05-10T11:04:53.000Z*
> The success of GLP-1 receptor agonists such as semaglutide and tirzepatide has driven attention to peptide drugs and inc

### [Highfine released its first-quarter performance, with a net profit attributable to the parent company of 34.799 million yuan, an increase of 16.66%](https://longbridge.com/zh-HK/news/237694817.md)
*2025-04-27T08:58:06.000Z*
> According to the Zhitong Finance APP, Highfine released its first-quarter report for 2025, with operating revenue of 135

### [](https://longbridge.com/zh-HK/news/237273763.md)
*2025-04-24T01:33:42.000Z*
> The A-share innovative drug concept was active at the beginning of the trading session, with Kingchem hitting the daily 

### [Highfine released its 2024 annual performance, with a net profit attributable to the parent company of 134 million yuan, an increase of 35.44%](https://longbridge.com/zh-HK/news/235402957.md)
*2025-04-10T10:38:04.000Z*
> Highfine released its 2024 annual report, with operating revenue of 452 million yuan, a year-on-year increase of 16.22%;